Abstract: The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies.

Abstract: The present invention provides a method for screening for iPS cells exhibiting differentiation resistance using a marker identified as lincRNA or mRNA that is specifically expressed in an iPS cell line exhibiting differentiation resistance, and such markers.

Abstract: A temperature measurement device includes a light emitting part including a first light source configured to output measurement light with a first wavelength and a second light source configured to output reference light with a second wavelength, a light receiving part configured to receive reflected light of the measurement light and reflected light of the reference light that have passed through a temperature sensing device that changes light transmission characteristics with changes in temperature, a control part configured to measure a temperature detected by the temperature sensing device based on an amount of light of the received reflected light of the measurement light and an amount of light of the received reflected light of the reference light, and a temperature adjustment part configured to separately adjust the temperature of the first light source and the temperature of the second light source.

Abstract: This relates to a method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.

Abstract: The present invention provides a method for screening for iPS cells exhibiting differentiation resistance using a marker identified as lincRNA or mRNA that is specifically expressed in an iPS cell line exhibiting differentiation resistance, and such markers.

Abstract: Provided is a method of improving the efficiency of iPS cell establishment, comprising bringing one or more factors selected from the group consisting of proteins belonging to cyclin D family and nucleic acids that encode the same into contact with a somatic cell, in the step of nuclear reprogramming of the somatic cell. Also provided are a method of producing an iPS cell comprising the step of bringing the factor(s) and nuclear reprogramming substance(s) into contact with a somatic cell, an iPS cell comprising a nucleic acid that encodes a protein belonging to cyclin D family that can be obtained by the method of producing an iPS cell, and a method of somatic cell production by forcing the iPS cell to differentiate.

Abstract: The present invention provides a method for screening drugs for suppressing inflammasome activity, using macrophages derived from induced pluripotent stem cells (iPS cells) having mutant NLRP3 gene.

Abstract: Provided is a method of improving the efficiency of establishment of induced pluripotent stem cells, comprising culturing somatic cells under hypoxic conditions in the step of nuclear reprogramming thereof.

Abstract: The invention provides a method of improving the efficiency of establishment of induced pluripotent stem cells by increasing, in a nuclear reprogramming step of somatic cell, the level of activated form of one or more proteins selected from the group consisting of Ras family members, PI3 kinase, RalGEF, Raf, AKT family members, Rheb, TCL1 and S6K. The invention also provides a method of producing induced pluripotent stem cells by contacting a somatic cell with a nuclear reprogramming substance and one or more of such proteins and nucleic acids that encode such proteins. The invention further provides an induced pluripotent stem cell that has an exogenous nucleic acid encoding such a protein, as well as agents for use in the aforesaid methods.

Abstract: A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an Oct family gene, a Klf family gene, a Sox family gene, a Myc family gene, a Lin family gene, and Nanog gene. The somatic cell is then cultured in a medium that supports pluripotent stem cells. At least a portion of the one or more introduced non-viral expression vectors is not substantially integrated in the chromosome.

Abstract: The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells by inhibiting p38 function in the step of somatic cell nuclear reprogramming. The 38 function can be inhibited by bringing an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway into contact with a somatic cell and the like.

Abstract: Provided is a method of producing an iPS cell, comprising bringing (a) Oct3/4 or a nucleic acid that encodes the same, (b) Klf4 or a nucleic acid that encodes the same, and (c) Sox2 or a nucleic acid that encodes the same, as well as (d1) L-Myc or a nucleic acid that encodes the same and/or (d2) a functional inhibitor of p53, into contact with a somatic cell. It is preferable that (a) a nucleic acid that encodes Oct3/4, (b) a nucleic acid that encodes Klf4, (c) a nucleic acid that encodes Sox2, (d1) a nucleic acid that encodes L-Myc and (e) a nucleic acid that encodes Lin28 or Lin28b be inserted into an episomal vector having loxP sequences placed in the same orientation on the 5? and 3? sides of a vector constituent essential for the replication of the vector, that (d2) a nucleic acid that encodes an shRNA against p53 be inserted into a vector ensuring transient expression (plasmid vector and the like), and that all these nucleic acids be transferred to a somatic cell.

Abstract: The present invention provides a method of screening for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome, comprising the following steps: (a) a step of forming colonies of hematopoietic progenitor cells induced from pluripotent stem (iPS) cells produced from non-T cells in blood mononuclear cells isolated from myelodysplastic syndrome patients, in the presence of a test substance and in the absence of the test substance, and (b) a step of selecting the test substance as a candidate for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome and the like when the colony number in the presence of the test substance increases from the colony number in the absence of the test substance.

Abstract: A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s).

Abstract: A method for sorting pluripotent cells using a compound which is eliminated from the pluripotent cells through the MDR1 transporter.

Abstract: The invention provides a method of producing iPS cells, which comprises the steps of (i) introducing reprogramming factors into somatic cells; (ii) culturing the cells obtained in step (i) for more than 11 days and not more than 29 days; (iii) sorting TRA-1-60-positive cells from the cells obtained in step (ii); (iv) culturing the TRA-1-60-positive cells sorted in step (iii); (v) transferring a colony obtained in step (iv) to another culture vessel; and (vi) culturing the cells obtained in step (v), thereby obtaining iPS cells. The cells obtained in step (v) are preferably subcultured 10 times or more. The invention also provides a method of producing a population of differentiated cells that has a reduced rate of residual undifferentiated cells, which comprises inducing differentiation of the iPS cells obtained by the above-mentioned method.

Abstract: The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies.

Abstract: A counterweight (9) provided on a rear side of an upper revolving structure (3) is formed as a block body in which a boundary position between a rear surface (9B) and the upper surface (9C) is a projected curved surface (9E) which is curved with a projected arc shape. A rear camera device (11) mounted on the upper surface (9C) of the counterweight (9) is arranged on the upper surface (9C) of the counterweight (9) and in a state protruding rearward toward the projected curved surface (9E) of the counterweight (9). On the other hand, a cover member (19) covering a gap (18) formed by the projected curved surface (9E) is provided between the projected curved surface (9E) of the counterweight (9) and a rear part lower surface (12F) of a mounting plate (12) of the rear camera device (11).

Abstract: The present invention provides a method of improving iPS cell establishment efficiency, comprising contacting a protein involved in primitive streak (PrS) formation, preferably Foxh1, or a nucleic acid that encodes the same with a somatic cell in a nuclear reprogramming step. Also provided is a method of producing an iPS cell, comprising contacting the protein involved in PrS formation or a nucleic acid that encodes the same, and nuclear reprogramming substance(s) with a somatic cell.

Abstract: The present invention provides a method for producing or detecting cardiomyocytes, which method comprises extracting/detecting cardiomyocytes from a cell population comprising cardiomyocytes using, as an index, positivity of NCAM1, SSEA3, SSEA4 and/or CD340.